Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
-
WiSe 2023
-
SoSe 2023
-
WiSe 2022
-
SoSe 2022
-
WiSe 2021
-
SoSe 2021
-
WiSe 2020
-
SoSe 2020
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancerIn: Therapeutic Advances in Medical Oncology , Jg. 13 2021DOI, Online Volltext (Open Access)
-
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expressionIn: Cancer Medicine , Jg. 9 2020, Nr. 13, S. 4527 – 4539DOI, Online Volltext (Open Access)
-
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasisIn: Oncogenesis , Jg. 9 2020, Nr. 11, S. 102DOI, Online Volltext (Open Access)
-
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS-TBNA Specimens From Patients With Lung AdenocarcinomaIn: Clinical Lung Cancer , Jg. 19 2018, Nr. 6, S. e879 – e884
-
Comprehensive biomarker analyses in patients with advanced or metastatic non-small cell lung cancer prospectively treated with the polo-like Kinase 1 Inhibitor BI2536In: Oncology Research and Treatment , Jg. 40 2017, Nr. 7-8, S. 435 – 439
-
Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancerIn: Journal of Cancer Research and Clinical Oncology , Jg. 143 2017, Nr. 9, S. 1733 – 1744
-
Inactivation of Capicua drives cancer metastasisIn: Nature Genetics , Jg. 49 2017, Nr. 1, S. 87 – 96DOI (Open Access)
-
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapyIn: OncoTarget , Jg. 8 2017, Nr. 28, S. 45898 – 45917DOI (Open Access)
-
Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung AdenocarcinomaIn: Journal of Thoracic Oncology , Jg. 12 2017, Nr. Suppl. 1, S. S1201 – S1201
-
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patientsIn: Journal of Cancer Research and Clinical Oncology , Jg. 142 2016, Nr. 4, S. 795 – 805
-
Alternative tumor suppressor mechanisms in lung carcinomas - modulation of senescence by growth factor-induced signalingIn: Cancer Research , Jg. 75 2015, Nr. 15 Suppl., S. 1033
-
MITF is a critical regulator of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in malignant melanomaIn: Pigment Cell and Melanoma Research , Jg. 28 2015, Nr. 6, S. 736 – 740
-
Molecular dissection of the impact of frequent genetic alterations on the response of head and neck cancers to anti-epidermal growth factor receptor-directed therapiesIn: Oral Oncology , Jg. 51 2015, Nr. 5, S. e39
-
Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST)In: Journal of Clinical Oncology (JCO) , Jg. 33 2015, Nr. 15_suppl, S. 10518
-
A Novel Sirtuin 2 (SIRT2) Inhibitor with p53-dependent Pro-apoptotic Activity in Non-small Cell Lung CancerIn: The Journal of Biological Chemistry (JBC) , Jg. 289 2014, Nr. 8, S. 5208 – 5216
-
Development of a Highly Sensitive and Specific Method for Detection of Circulating Tumor Cells Harboring Somatic Mutations in Non-Small-Cell Lung Cancer PatientsIn: PLoS ONE , Jg. 9 2014, Nr. 1, e85350DOI (Open Access)
-
Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunityIn: Cell Death and Disease , Jg. 5 2014, Nr. 12, 1568DOI (Open Access)
-
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyIn: Cell Death and Disease , Jg. 5 2014, Nr. 2, e1091DOI (Open Access)
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research , Jg. 73 2013, Nr. 12, S. 3661 – 3670
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) , Jg. 49 2013, Nr. 15, S. 3076 – 3082
-
Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockadeIn: Oncogene , Jg. 32 2013, Nr. 23, S. 2873 – 2881
-
Stabilization of Physical RAF/14-3-3 Interaction by Cotylenin A as Treatment Strategy for RAS Mutant CancersIn: ACS Chemical Biology , Jg. 8 2013, Nr. 9, S. 1869 – 1875
-
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancerIn: Journal of Cancer Research and Clinical Oncology , Jg. 138 2012, Nr. 8, S. 1385 – 1394
-
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancerIn: Journal of Cancer Research and Clinical Oncology , Jg. 138 2012, Nr. 4, S. 545 – 554
-
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesIn: Blood Cancer Journal , Jg. 2 2012, Nr. 3, S. e60DOI (Open Access)
-
Targeting the anti-apoptotic protein BCL-XL to overcome RAS mediated resistance to anti-EGFR antibody therapy in colorectal cancerIn: Onkologie , Jg. 35 2012, Nr. Suppl. 6, S. 253
-
VVTZ-Tumorprofil - First results of a preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer CenterIn: Onkologie , Jg. 35 2012, Nr. Suppl. 6, S. 204 – 204
-
Zug um Zug : Tumorzellen in Schach halten – Moderne Konzepte zur Behandlung des LungenkarzinomsIn: Unikate: Berichte aus Forschung und Lehre 2012, Nr. 42: Translationale Krebsforschung: Auf dem Weg zu neuen Therapien, S. 90 – 97DOI, Online Volltext (Open Access)
-
Evaluation of Betav-Tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancerIn: Journal of Thoracic Oncology , Jg. 6 2011, Nr. Suppl. 6, S. 1078
-
Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung CancerIn: Journal of Thoracic Oncology , Jg. 6 2011, Nr. 12, S. 1976 – 1983DOI (Open Access)
-
Pharmacological Inhibition of NF-k and PLK-1 to the Opening of the RAS-mediated Resistance to anti-EGFR Antibody therapies in Colorectal cancer *In: Der Internist , Jg. 52 2011, Nr. 6, S. 726 – 726
-
Simultaneous protection against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR-signaling blockade by oncogenic RASIn: Journal of Clinical Oncology (JCO) , Jg. 29 2011, Nr. Suppl. 4, S. 440
-
Individualisierte Therapie für Patienten mit fortgeschrittenen LungenkarzinomenIn: TumorDiagnostik & Therapie , Jg. 31 2010, Nr. 2, S. 79 – 87
-
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathwayIn: Oncogene , Jg. 29 2010, Nr. 5, S. 739 – 751DOI (Open Access)
-
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptorIn: Blood , Jg. 113 2009, Nr. 17, S. 4074 – 4077
-
MA17.07 Identification of AHR as a Novel Regulator of Lung Cancer MetastasisIn: Journal of Thoracic Oncology , Jg. 14 2019, Nr. 10, Supplement, S. S319DOI (Open Access)
-
Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 10.-14. Oktober 2014, Hamburg,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 5, S. 226 – 227 -
Impact of human papilloma virus infection on the response of head and neck cancers (HNSCC) to anti-epidermal growth factor receptor (EGFR) antibody therapy
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment , Jg. 37 2014, Nr. Suppl. 1, S. 76 -
Molecular dissection of effector mechanisms of RAS-induced resistance to monoclonal anti-EGFR antibodies
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie , Jg. 36 2013, Nr. Suppl. 7, S. 116 – 117 -
Functional characterization of DOG1 in Gastrointestinal Stromal Tumors (GIST)In: Cancer Research , Jg. 72 2012, Nr. 8, Suppl., S. 1824
-
Impact of EGFR mutation status on clinical benefit from BIBW 2992 in patients (PTS) with advanced non-small lung cancer (NSCLC) progressing after chemotherapy (CTX) and erlotinib (E) or gefitinib (G) : a single center experience
37th ESMO Congress, 28 September - 2 October 2012, Vienna, Austria,In: Annals of Oncology , Jg. 23 2012, Nr. Suppl. 9, S. 437 – 438 -
Inhibitors of apoptosis (IAPs) in gastrointestinal stromal tumorsIn: Cancer Research , Jg. 72 2012, Nr. 8, Suppl., S. 3855 – 3855
-
Influence of Everolimus and Pemetrexed on Thymidylate Synthase expression as well as on Proliferation and survival of non-small cell ling Cancer CellsIn: Journal of Thoracic Oncology , Jg. 5 2010, Nr. Suppl. 1, S. S56 – S57
-
Highly sensitive detection of somatic epidermal growth factor receptor (EGFR) gene mutations in circulating tumor cells (CTC) from patients with non-small cell lung cancer treated with cisplatin/pemetrexed or afatinib
14th World Conference on Lung Cancer, July 3 – 7, 2011, Amsterdam, The Netherlands,In: Journal of Thoracic Oncology , Jg. 6 2011, Nr. 6, Suppl. 2, S. S956 – S957